Literature DB >> 34755596

The Evaluation of Iron Deficiency and Iron Overload

Norbert Gattermann1, Martina U Muckenthaler, Andreas E Kulozik, Georgia Metzgeroth, Jan Hastka.   

Abstract

BACKGROUND: In the western world, 10-15% of women of child-bearing age suffer from iron-deficiency anemia. Iron overload due to chronic treatment with blood transfusions or hereditary hemochromatosis is much rarer.
METHODS: This review is based on pertinent publications retrieved by a selective search on the pathophysiology, clinical features, and diagnostic evaluation of iron deficiency and iron overload.
RESULTS: The main causes of iron deficiency are malnutrition and blood loss. Its differential diagnosis includes iron-refractory iron deficiency anemia (IRIDA), a rare congenital disease in which the hepcidin level is pathologically elevated, as well as the more common anemia of chronic disease (anemia of chronic inflammation), in which increased amounts of hepcidin are formed under the influence of interleukin-6 and enteric iron uptake is blocked as a result. Iron overload comes about through long-term transfusion treatment or a congenital disturbance of iron metabolism (hemochromatosis). Its diagnostic evaluation is based on clinical and laboratory findings, imaging studies, and specific mutation analyses.
CONCLUSION: Our improving understanding of the molecular pathophysiology of iron metabolism aids in the evaluation of iron deficiency and iron overload and may in future enable treatment not just with iron supplementation or iron chelation, but also with targeted pharmacological modulation of the hepcidin regulatory system.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34755596      PMCID: PMC8941656          DOI: 10.3238/arztebl.m2021.0290

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  38 in total

Review 1.  Characteristics of the arthropathy described in hereditary hemochromatosis.

Authors:  G J Carroll; W H Breidahl; J K Olynyk
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-01       Impact factor: 4.794

Review 2.  Global look at nutritional and functional iron deficiency in infancy.

Authors:  Michael B Zimmermann
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

3.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

Authors:  Luca Malcovati; Matteo Giovanni Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Marina Boni; Erica Travaglino; Francesco Passamonti; Luca Arcaini; Margherita Maffioli; Paolo Bernasconi; Mario Lazzarino; Mario Cazzola
Journal:  J Clin Oncol       Date:  2005-09-26       Impact factor: 44.544

Review 4.  Survival and complications in thalassemia.

Authors:  C Borgna-Pignatti; M D Cappellini; P De Stefano; G C Del Vecchio; G L Forni; M R Gamberini; R Ghilardi; R Origa; A Piga; M A Romeo; H Zhao; A Cnaan
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

Review 5.  A Red Carpet for Iron Metabolism.

Authors:  Martina U Muckenthaler; Stefano Rivella; Matthias W Hentze; Bruno Galy
Journal:  Cell       Date:  2017-01-26       Impact factor: 41.582

6.  Serum ferritin, liver iron stores, and liver histology in children with thalassaemia.

Authors:  S de Virgiliis; G Sanna; G Cornacchia; F Argiolu; V Murgia; M Porcu; A Cao
Journal:  Arch Dis Child       Date:  1980-01       Impact factor: 3.791

7.  Erythroferrone inhibits the induction of hepcidin by BMP6.

Authors:  João Arezes; Niall Foy; Kirsty McHugh; Anagha Sawant; Doris Quinkert; Virginie Terraube; Alette Brinth; May Tam; Edward R LaVallie; Stephen Taylor; Andrew E Armitage; Sant-Rayn Pasricha; Orla Cunningham; Matthew Lambert; Simon J Draper; Reema Jasuja; Hal Drakesmith
Journal:  Blood       Date:  2018-08-10       Impact factor: 22.113

Review 8.  Erythroferrone structure, function, and physiology: Iron homeostasis and beyond.

Authors:  Daniel N Srole; Tomas Ganz
Journal:  J Cell Physiol       Date:  2020-12-28       Impact factor: 6.513

Review 9.  Iron metabolism and iron supplementation in cancer patients.

Authors:  Heinz Ludwig; Rayko Evstatiev; Gabriela Kornek; Matti Aapro; Thomas Bauernhofer; Veronika Buxhofer-Ausch; Michael Fridrik; Dietmar Geissler; Klaus Geissler; Heinz Gisslinger; Elisabeth Koller; Gerhard Kopetzky; Alois Lang; Holger Rumpold; Michael Steurer; Houman Kamali; Hartmut Link
Journal:  Wien Klin Wochenschr       Date:  2015-09-15       Impact factor: 1.704

Review 10.  Iron metabolism and iron disorders revisited in the hepcidin era.

Authors:  Clara Camaschella; Antonella Nai; Laura Silvestri
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

View more
  7 in total

1.  Iron Balance in Chronic Kidney Disease.

Authors:  A Alexopoulos
Journal:  Dtsch Arztebl Int       Date:  2022-06-17       Impact factor: 8.251

2.  In Reply.

Authors:  Norbert Gattermann
Journal:  Dtsch Arztebl Int       Date:  2022-06-17       Impact factor: 8.251

3.  Reference Ranges Should Be Updated.

Authors:  Norbert Ostendorf
Journal:  Dtsch Arztebl Int       Date:  2022-06-17       Impact factor: 8.251

4.  Take into Account Variations of Transferrin Saturation.

Authors:  H Tilman Steinmetz
Journal:  Dtsch Arztebl Int       Date:  2022-06-17       Impact factor: 8.251

Review 5.  The Roles and Pathogenesis Mechanisms of a Number of Micronutrients in the Prevention and/or Treatment of Chronic Hepatitis, COVID-19 and Type-2 Diabetes Mellitus.

Authors:  Khalid M Sumaily
Journal:  Nutrients       Date:  2022-06-24       Impact factor: 6.706

6.  Association Between Serum Iron Status and Muscle Mass in Adults: Results From NHANES 2015-2018.

Authors:  Zhi Chen; Jing Chen; Chenyang Song; Jun Sun; Wenge Liu
Journal:  Front Nutr       Date:  2022-07-11

Review 7.  Iron, Neuroinflammation and Neurodegeneration.

Authors:  Roberta J Ward; David T Dexter; Robert R Crichton
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.